Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | TAS1R3 | Q7RTX0 | 13/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 13/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5133204 | 0.88 | TAS1R3 (0.50) | TAS1R3TAS1R1CHRM1AKR1A1CHRM3 | |
| SCHEMBL4820679 | 0.87 | PLA2G2C (0.46) | CNR2 | |
| SCHEMBL16762206 | 0.87 | PLA2G2C (0.46) | CNR2 | |
| SCHEMBL4820666 | 0.87 | PLA2G2C (0.46) | CNR2 | |
| SCHEMBL6120544 | 0.84 | TAS1R3 (0.44) | TAS1R3TAS1R1CHRM1AKR1A1CHRM3 | |
| SCHEMBL6717845 | 0.84 | TAS1R3 (0.50) | TAS1R3TAS1R1CHRM1AKR1A1CHRM3 | |
| SCHEMBL3888142 | 0.84 | PLA2G2C (0.47) | — | |
| SCHEMBL11050261 | 0.84 | PLA2G2C (0.47) | — | |
| SCHEMBL3884103 | 0.84 | PLA2G2C (0.47) | — | |
| SCHEMBL7549777 | 0.84 | PLA2G2C (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012067269-A1 | AMINOALKOXYPHENYL COMPOUNDS AND THEIR USE IN THE TREATMENT OF DISEASE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-05-24 | — | — | WO | disclosed |
| US-20090156624-A1 | Methionine aminopeptidase-2 inhibitors and methods of use thereof | PRAECIS PHARMACEUTICALS INC (US) | 2009-06-18 | — | — | US | disclosed |
| US-7405194-B2 | Therapeutic agents and methods of use thereof for the treatment of melanoma | PRAECIS PHARMACEUTICALS, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-7348307-B2 | Methionine aminopeptidase-2 inhibitors and methods of use thereof | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2008-03-25 | — | — | US | disclosed |
| US-7268111-B2 | Therapeutic agents and methods of use thereof for the modulation of angiogenesis | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-09-11 | — | — | US | disclosed |
| US-20070161570-A1 | Methionine aminopeptidase-2 inhibitors and methods of use thereof | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070117758-A1 | Therapeutic agents and methods of use thereof for the modulation of angiogenesis | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-05-24 | — | — | US | disclosed |
| US-20070010452-A1 | Methionine aminopeptidase-2 inhibitors and methods of use thereof | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-01-11 | — | — | US | disclosed |
| US-7157420-B2 | Therapeutic agents and methods of use thereof for the modulation of angiogenesis | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-20060223758-A1 | Therapeutic agents and methods of use thereof for the modulation of angiogenesis | PRAECIS PHARMACEUTICALS, INC. (US) | 2006-10-05 | — | — | US | disclosed |
| US-7084108-B2 | Therapeutic agents and methods of use thereof for the modulation of angiogenesis | PRAECIS PHARMACEUTICALS, INC. (US) | 2006-08-01 | — | — | US | disclosed |
| US-7037890-B2 | Therapeutic agents and methods of use thereof for the modulation of angiogenesis | PRAECIS PHARMACEUTICALS, INC. (US) | 2006-05-02 | — | — | US | disclosed |
| US-20060069028-A1 | Therapeutic agents and methods of use thereof for the modulation of angiogenesis | PRAECIS PHARMACEUTICALS, INC. (US) | 2006-03-30 | — | — | US | disclosed |
| US-6919307-B2 | Therapeutic agents and methods of use thereof for the modulation of angiogenesis | PRAECIS PHARMACEUTICALS, INC. (US) | 2005-07-19 | — | — | US | disclosed |
| US-20050130903-A1 | Therapeutic agents and methods of use thereof for the modulation of angiogenesis | GLAXOSMITHKLINE LLC | 2005-06-16 | — | — | US | disclosed |
| US-20050059585-A1 | Methionine aminopeptidase-2 inhibitors and methods of use thereof | PRAECIS PHARMACEUTICALS INC. (US) | 2005-03-17 | — | — | US | disclosed |
| US-20030109671-A1 | Therapeutic agents and methods of use thereof for the modulation of angiogenesis | PRAECIS PHARMACEUTICALS INC. | 2003-06-12 | — | — | US | disclosed |
| US-6548477-B1 | A carbamate or urea containing comopound is useful to treat angiogeneisis; methionine aminopeptidase 2 (MetAP-2) coupled to a peptide prevents the metabolic degradation of the angiogenesis inhibitor compound | PRAECIS PHARMACEUTICALS INC. | 2003-04-15 | — | — | US | disclosed |
| US-20020193298-A1 | Therapeutic agents and methods of use thereof for the modulation of angiogenesis | PRAECIS PHARMACEUTICALS INC. | 2002-12-19 | — | — | US | disclosed |
| US-20020151493-A1 | Therapeutic agents and methods of use thereof for the modulation of angiogenesis | PRAECIS PHARMACEUTICALS INC. | 2002-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010452-A1 | Methionine aminopeptidase-2 inhibitors and methods of use thereof | METAP2, METAP1, DNPEP | CNR1 4725/4885TAS1R3 4021/4885TAS1R1 4205/4885 |
| US-20030109671-A1 | Therapeutic agents and methods of use thereof for the modulation of angiogenesis | METAP2, METAP1, ADM2 | CNR1 3196/4885TAS1R3 4260/4885TAS1R1 4415/4885 |
| US-20060223758-A1 | Therapeutic agents and methods of use thereof for the modulation of angiogenesis | METAP2, METAP1, ADM2 | CNR1 3196/4885TAS1R3 4260/4885TAS1R1 4415/4885 |
| US-20020193298-A1 | Therapeutic agents and methods of use thereof for the modulation of angiogenesis | METAP2, METAP1, ADM2 | CNR1 3196/4885TAS1R3 4260/4885TAS1R1 4415/4885 |
| US-20050130903-A1 | Therapeutic agents and methods of use thereof for the modulation of angiogenesis | METAP2, METAP1, ADM2 | CNR1 3196/4885TAS1R3 4260/4885TAS1R1 4415/4885 |
| US-20050059585-A1 | Methionine aminopeptidase-2 inhibitors and methods of use thereof | METAP2, METAP1, LNPEP | CNR1 4612/4885TAS1R3 3843/4885TAS1R1 4044/4885 |
| US-20070117758-A1 | Therapeutic agents and methods of use thereof for the modulation of angiogenesis | METAP2, METAP1, ADM2 | CNR1 3196/4885TAS1R3 4260/4885TAS1R1 4415/4885 |
| US-20060069028-A1 | Therapeutic agents and methods of use thereof for the modulation of angiogenesis | METAP2, METAP1, ADM2 | CNR1 3196/4885TAS1R3 4260/4885TAS1R1 4415/4885 |
| US-20020151493-A1 | Therapeutic agents and methods of use thereof for the modulation of angiogenesis | METAP2, METAP1, ADM2 | CNR1 3196/4885TAS1R3 4260/4885TAS1R1 4415/4885 |
| US-20070161570-A1 | Methionine aminopeptidase-2 inhibitors and methods of use thereof | METAP2, METAP1, LNPEP | CNR1 4072/4885TAS1R3 4097/4885TAS1R1 4163/4885 |
| US-20090156624-A1 | Methionine aminopeptidase-2 inhibitors and methods of use thereof | METAP2, METAP1, DNPEP | CNR1 4725/4885TAS1R3 4021/4885TAS1R1 4205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.